The global eisenmenger syndrome treatment market is anticipated to grow at a CAGR during the forecast period. The triad of systemic-to-pulmonary congenital cardiovascular communication, pulmonary arterial disease, and cyanosis is called Eisenmenger syndrome. The major factor that drives the market is consistent regulatory approval to the key players operating in the global market for the treatment of Eisenmenger syndrome by providing drugs, and therapy is expected to drive the market growth. for instance-
July 2021- The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US Food and Drug Administration (FDA) has approved UPTRAVI (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy. UPTRAVI IV is a therapeutic option that will allow patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy, as uninterrupted treatment is considered key for individuals with PAH.
April 2021- The US FDA has granted a second approval to treprostinil (Tyvaso) inhalation solution, for the patines. Tyvaso DPI is the only therapy approved by the FDA for PH-ILD, when the blood pressure in the lungs is high due to a disease that causes lung scarring. Moreover, the convenience and portability of Tyvaso DPI make it an important new option for patients with WHO Group 1 PAH and with WHO Group 3 PH-ILD, with the potential for improving the quality of life for this patient population.
To Request a Sample of our Report on Eisenmenger Syndrome Treatment Market: https://www.omrglobal.com/request-sample/eisenmenger-syndrome-treatment-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered- by drug type, by diagnosis, by distribution channel
Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
Competitive Landscape includes- AstraZeneca, Bayer AG, Johnson & Johnson Pte. Ltd Pharmaceuticals Corp., Pfizer Inc., GlaxoSmithKline,Hikma Pharmaceuticals PLC, and others.
Eisenmenger Syndrome Treatment Market– Segmentation
by Drug Type
- Antiarrhythmic Agents
- Blood Thinning Agents
- Endothelin Receptor Antagonist
- Others
By Diagnosis
- Blood tests
- Electrocardiogram (ECG)
- Chest X-ray
- Echocardiogram
- Computerized tomography (CT) scan
- Magnetic resonance imaging (MRI)
- Cardiac catheterization
By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
A full Report of Eisenmenger Syndrome Treatment Market is Available @ https://www.omrglobal.com/industry-reports/eisenmenger-syndrome-treatment-market
Eisenmenger Syndrome Treatment Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East and Africa
Company Profiles
- Eli Lilly and Co.
- Gilead Sciences, Inc.
- GlaxoSmithKline
- Hikma Pharmaceuticals PLC
- Lupin Ltd.
- Merck & Co., Inc.
- Natco Pharma Ltd.
- Sun Pharma
- Viatris Inc
- Zydus Pharmaceuticals (USA) Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/eisenmenger-syndrome-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
